Taggart D P, D'Amico R, Altman D G
Oxford Heart Centre, John Radcliffe Hospital, OX3 9DU, Oxford, UK.
Lancet. 2001 Sep 15;358(9285):870-5. doi: 10.1016/S0140-6736(01)06069-X.
Coronary artery bypass grafting (CABG) is the commonest major operation in most developed countries. A single internal mammary artery (IMA) graft has proven survival benefits, but the additional survival advantage of a second graft is unknown. We systematically reviewed published studies of bilateral versus single IMA grafts in CABG to assess any differences in survival.
We identified from Medline all studies in which single and bilateral IMA grafts were compared. We included studies in which at least 100 patients in each group had been followed up for at least 4 years. We assessed study quality on the basis of patient selection, comparability of intervention groups (especially for age, sex, ventricular function, and diabetes status), outcome assessment, and completeness of follow-up. Our primary outcome was survival. Estimates of treatment effect (single versus bilateral) expressed as hazard ratios were pooled across studies.
None of the studies was a randomised trial, but nine cohort studies met our inclusion criteria. Seven studies yielded survival data for meta-analysis, and included 15962 patients: 11269 single and 4693 bilateral IMA grafts. The bilateral group had significantly better survival than the single group (hazard ratio for death 0.81; 95% CI 0.70-0.94). Exclusion of methodologically weak studies improved survival rates with bilateral IMA grafts.
Because no study was a randomised trial, our results are more uncertain than is indicated by the 95% CI. Nevertheless, bilateral IMA grafts seem to give better survival rates than single grafts.
冠状动脉旁路移植术(CABG)是大多数发达国家最常见的大型手术。单支乳内动脉(IMA)移植已被证明具有生存益处,但第二支移植的额外生存优势尚不清楚。我们系统回顾了已发表的关于CABG中双侧与单支IMA移植的研究,以评估生存方面的任何差异。
我们从Medline中识别出所有比较单支和双侧IMA移植的研究。我们纳入了每组至少100例患者且随访至少4年的研究。我们根据患者选择、干预组的可比性(特别是年龄、性别、心室功能和糖尿病状态)、结局评估以及随访的完整性来评估研究质量。我们的主要结局是生存。将以风险比表示的治疗效果估计值(单支与双侧)在各项研究中进行汇总。
没有一项研究是随机试验,但有9项队列研究符合我们的纳入标准。7项研究产生了用于荟萃分析的生存数据,共纳入15962例患者:11269例接受单支IMA移植,4693例接受双侧IMA移植。双侧组的生存率显著高于单支组(死亡风险比为0.81;95%置信区间为0.70 - 0.94)。排除方法学上较弱的研究后,双侧IMA移植的生存率有所提高。
由于没有研究是随机试验,我们的结果比95%置信区间所显示的更不确定。尽管如此,双侧IMA移植似乎比单支移植有更好的生存率。